All In Biotech

Drug Trial Radar · NCT03309163

Effect of Tramadol in Prevention of Postpartum Depression

Last checked: Nov 19, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,230 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,230

Actual

Start

Oct 9, 2017

Primary completion

Jun 13, 2019

Study completion Aug 13, 2019

Sponsor

Lead sponsor
Xinqiao Hospital of ChongqingAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The incidence of postpartum depression in Europe and the United States is about 10%, while in China the incidence rate of 15.7-39.8%. Postpartum depression is one of the most common diseases of perinatal distress, but the current research of high-quality prevention and treatment of postpartum depression is still very lack. The study suggests that the risk of postpartum depression in cesarean delivery is significantly higher than that in vaginal delivery. Therefore, postpartum depression in cesarean delivery may require more attention and treatment.Tramadol is a non-opioid central analgesic that relieves common to severe pain, and tramadol has an inhibitory effect on norepinephrine and serotonin systems and has the potential to reduce depression and anxiety. Therefore, for the analgesic demand and antidepressant demand for maternal who undergoing cesarean section, tramadol may be an optimized and effective analgesic for the prevention and treatment of postpartum depression.

Conditions

  • Caesarean Section

Interventions

  • TramadolDrug

    Patient-controlled intravenous analgesia with Tramadol

  • HydromorphoneDrug

    Patient-controlled intravenous analgesia with Hydromorphone

  • Ropivacaine (Epidural analgesia)Drug

    Patient-controlled epidural analgesia with Ropivacaine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of postpartum depressionTime frame: At 4 weeks after the surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xinqiao Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.